IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

June 20, 2025 at 13:15 PM EDT

PITTSBURGH, PA / ACCESS Newswire / June 20, 2025 / Law Office of Alfred G. Yates Jr. PC announces investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. - Immunovant's controlling stockholder - in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant shares at a price of $20.00 per share, a $3.48 per share discount to the prior trading day's closing price.

If you are currently an Immunovant investor and would like to learn more, you can provide your information here: https://yatesclassactionlaw.com/

Contact attorney Alfred G. Yates, Jr. by calling (412) 391-5164 or via e-mail at yateslaw@aol.com.

THE COMPANY: Immunovant is a clinical-stage immunology company. In December 2019, a blank check company under the name Health Sciences Acquisitions Corporation ("HSAC") merged with Immunovant Sciences Ltd., which was a majority-owned subsidiary of Roivant. Subsequent to the merger, HSAC changed its name to Immunovant, Inc. At all times since the merger, Roivant has controlled a majority of Immunovant's stock, holding between 54.6% and 73.8% of Immunovant's shares.

THE TRANSACTION: On January 13, 2025, Immunovant announced, prior to the start of trading, that it had entered into a share purchase agreement with Roivant. Pursuant to the agreement, Immunovant sold 16,845,010 shares of the company's common stock to Roivant via a private placement for $20.00 per share, a $3.48 per share discount to the prior trading day's closing price. The last time Immunovant's share price had closed as low as $20.00 per share was in August 2023 - nearly a year and a half before the private placement. This $3.48 per share discount, when multiplied by the 16,845,010 shares Roivant received pursuant to the agreement, equates to a benefit to Roivant of nearly $60 million at the expense of Immunovant and its shareholders.

Past results do not guarantee future outcomes.

Services may be performed by attorneys in any of our offices.

Contacts

Alfred G. Yates Jr., Esquire
Law Office of Alfred G. Yates Jr. PC
(412) 391-5164
1-844-391-5164
yateslaw@aol.com
yatesclassactionlaw.com

SOURCE: Law Office of Alfred G. Yates, Jr., P.C.

View the original press release on ACCESS Newswire

About Us

Additional Information

Website & Technical Help

IMVT INVESTIGATION ALERT: Pittsburgh Law Office of Alfred G. Yates Jr. PC Announces Investigation into a Private Placement Transaction by Immunovant, Inc. and Encourages Investors to Contact the Firm

More News